Harrow, Inc.

HROW · Nasdaq · United States

Share price · HROW

$32.16-7.36 (-18.62%) 3M

close as of 2026-11-18 · 24h delayed · vol 865K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when HROW's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026+8.9%
  2. 13 Nov 2026+6.4%
  3. 10 Nov 2026+10.5%
  4. 10 Jun 2026+7.3%
  5. 12 May 2026-23.7%
  6. 3 Mar 2026-28.0%
  7. 2 Feb 2026+9.7%
  8. 9 Jan 2026-8.3%

    Nothing announced by HROW that day or the session before.

  9. 5 Jan 2026+9.8%

    Nothing announced by HROW that day or the session before.

  10. 12 Dec 2025-7.9%

    Nothing announced by HROW that day or the session before.

Share of unusual movement by asset

For each asset, the share of HROW's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(4 total)
4Total Assets
4Approved
0Phase 3 / Filed
0Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Approved
VEGF-AProtein / enzyme therapeutic
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Approved
Voltage-gated sodium channels (Nav) on sensory nerve membranesSmall molecule
Ocular Anesthesia
Ocular Surface Anesthesia
Approved
CalcineurinSmall molecule
Dry Eye Disease
Approved
VEGF-AMonoclonal antibody
Age-Related Macular Degeneration
Wet Age-Related Macular Degeneration

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 August 2026Topline resultchloroprocaineIHEEZO contralateral-eye study vs proparacaine in intravitreal injections

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$99M$10M$75M—-$8.6M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$71M$8.1M$84M$17M-$9.8M operating cash flowreport ↗
2026-Q1$44M$5.9M$95M$28M-$9.0M operating cash flowreport ↗
2025-Q3$72M$3.3M$74M—$17M operating cash flowreport ↗
2025-Q2$64M$2.9M$53M—-$0.8M operating cash flowreport ↗
2025-Q1$48M$3.0M$67M$18M$20M operating cash flowreport ↗
2024-Q3$49M$2.3M$73M$4.2M$3.0M operating cash flowreport ↗
2024-Q2$49M$3.0M$71M$6.5M-$2.8M operating cash flowreport ↗
2024-Q1$35M$2.1M$69M+ $7.4M short-term inv.$14M-$4.6M operating cash flowreport ↗
2023-Q3$34M$1.4M$66M+ $8.3M short-term inv.$4.4M-$1.2M operating cash flowreport ↗
2023-Q2$33M$1.2M—+ $6.9M short-term inv.$4.2M$4.6M operating cash flowreport ↗
2023-Q1$26M$0.7M—+ $7.6M short-term inv.$6.6M-$8.2M operating cash flowreport ↗
2022-Q3$23M$0.8M$45M+ $4.2M short-term inv.$6.5M-$0.4M operating cash flowreport ↗
2022-Q2$23M$0.9M$46M+ $5.2M short-term inv.$6.2M$4.9M operating cash flowreport ↗
2022-Q1$22M$0.7M$42M+ $8.6M short-term inv.$2.4M$1.0M operating cash flowreport ↗
2021-Q3$19M$6.1M$58M+ $10.0M short-term inv.$8.3M-$2.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$272M$21M$73M$1.3M$44M operating cash flowreport ↗

For the full year 2025, Harrow reported revenue of $272.3M, up 36.4% YoY, with R&D spend of $20.94M, up 71.2% YoY. Cash and equivalents stood at $72.93M, and the company recorded a net loss of $5.14M for the year.

The company issued 2026 revenue guidance of $350M to $365M, including $133M to $153M in the first half and $203M to $226M in the second half, alongside Adjusted EBITDA guidance of $80M to $100M. Harrow highlighted advancement of its development pipeline, including G-MELT, YOCHIL, and a next-generation TRIESENCE pre-filled syringe, and noted the 2025 acquisition of Melt Pharmaceuticals, which drove $8.5M of acquired in-process R&D expense. The company also generated $43.9M of operating cash flow in 2025 versus $(22.2)M used in 2024.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$200M$12M$47M$4.4M-$22M operating cash flowreport ↗
2023-FY$130M$6.7M$74M+ $8.7M short-term inv.$6.1M$3.8M operating cash flowreport ↗
2022-FY$89M$3.0M$96M+ $5.6M short-term inv.$3.5M$1.7M operating cash flowreport ↗
2021-FY$72M$11M$42M+ $8.5M short-term inv.$4.5M$5.1M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 4 purchases ($469K), 7 sales ($9.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-14Shojaei Amir · CHIEF SCIENTIFIC OFFICEROption exercise11,250$35.96$405KForm 4
2026-08-14Shojaei Amir · CHIEF SCIENTIFIC OFFICEROpen-market sale11,250$40.00$450KForm 4
2026-08-14Shojaei Amir · CHIEF SCIENTIFIC OFFICEROption exercise (derivative)11,250$35.96$405KForm 4
2026-06-18Graves Adrienne L · directorAward / grant (derivative)5,248——Form 4
2026-06-18SILVERNAIL LAUREN P · directorAward / grant (derivative)5,248——Form 4
2026-06-18Sternberg Perry J. · directorAward / grant (derivative)5,248——Form 4
2026-05-18SILVERNAIL LAUREN P · directorOpen-market purchase1,000$31.00$31KForm 4
2026-05-18Graves Adrienne L · directorOpen-market purchase1,000$31.07$31KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 217 reporting institutions held 21.4M shares ($752.8M, 57.0% of shares outstanding).

#InstitutionSharesValue
1Opaleye Management Inc.2,832,230$99.9M
2BlackRock, Inc.2,552,759$90.0M
3Private Capital Management, LLC1,562,000$55.1M
4VANGUARD CAPITAL MANAGEMENT LLC1,403,056$49.5M
5Luxor Capital Group, LP1,119,400$39.5M
6STATE STREET CORP855,047$30.1M
7GEODE CAPITAL MANAGEMENT, LLC852,034$30.0M
8MARSHALL WACE, LLP644,918$22.7M
9DIMENSIONAL FUND ADVISORS LP579,520$20.4M
10Ikarian Capital, LLC543,047$19.1M
11SUSQUEHANNA INTERNATIONAL GROUP, LLP457,782$16.1M
12Penn Capital Management Company, LLC407,896$14.4M
13RICE HALL JAMES & ASSOCIATES, LLC368,177$13.0M
14GOLDMAN SACHS GROUP INC341,707$12.0M
15NORTHERN TRUST CORP296,865$10.5M